Greenwood Capital Associates LLC Has $8.90 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Greenwood Capital Associates LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 11,528 shares of the biopharmaceutical company’s stock after selling 1,063 shares during the period. Regeneron Pharmaceuticals accounts for 1.0% of Greenwood Capital Associates LLC’s holdings, making the stock its 26th biggest position. Greenwood Capital Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $8,898,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its position in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after buying an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $3,183,000. Gabelli Funds LLC raised its position in Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after buying an additional 55 shares during the last quarter. Finally, Sei Investments Co. raised its position in Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after buying an additional 5,120 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,774 shares of company stock worth $2,942,738 in the last quarter. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ:REGN opened at $753.93 on Thursday. The company has a market capitalization of $79.71 billion, a PE ratio of 18.14, a price-to-earnings-growth ratio of 2.01 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The business has a fifty day moving average price of $766.75 and a two-hundred day moving average price of $723.97. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Analysts Set New Price Targets

A number of research firms recently commented on REGN. Evercore increased their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday, January 22nd. Morgan Stanley boosted their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. JPMorgan Chase & Co. boosted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Barclays initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, March 6th. They set an “overweight” rating and a $923.00 price target on the stock. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $811.96.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.